Callan Family Office LLC Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Callan Family Office LLC purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 2,165 shares of the specialty pharmaceutical company’s stock, valued at approximately $267,000.

Other large investors have also modified their holdings of the company. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Jones Financial Companies Lllp raised its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 130 shares during the period. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 129 shares during the period. Lindbrook Capital LLC raised its holdings in shares of Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 176 shares during the period. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Barclays reiterated an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Piper Sandler reiterated an “overweight” rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Finally, HC Wainwright upped their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $190.53.

Jazz Pharmaceuticals Trading Down 1.0 %

JAZZ opened at $137.45 on Tuesday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The company has a market cap of $8.35 billion, a P/E ratio of 19.36, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business’s 50-day simple moving average is $128.43 and its 200-day simple moving average is $120.23.

Insider Activity

In other news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,193 shares of company stock worth $3,533,122. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.